SUPERNUS PHARMACEUTICALS, INC. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $14.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2022-11-09
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2022-09-30 was $1.00K, a 50.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2022-06-30 was $13.00K, a 333.33% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2021-09-30 was $2.00K, a 99.38% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2018 was -$8.00K.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2022-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $14.00K derived: sum of 2 quarters · filed 2022-11-09 | $14.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $13.00K 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $5.00K derived: sum of 2 quarters · filed 2022-11-09 | $221.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $219.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $216.00K 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | $320.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $3.43M derived: sum of 2 quarters · filed 2021-11-05 | $3.64M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $3.32M 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $202.00K 10-Q · filed 2021-05-07 | |||
| 2019-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $123.00K derived: sum of 2 quarters · filed 2020-11-06 | $131.00K 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $93.00K 10-Q · filed 2020-08-17 | ||
| 2019-03-31 | $8.00K 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | -$8.00K 10-K · filed 2019-03-01 | |||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |